KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Non-Current Debt data on record, last reported at $27.5 million in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 15.33% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $27.5 million, down 15.33%, while the annual FY2025 figure was $27.5 million, 15.33% down from the prior year.
  • Non-Current Debt reached $27.5 million in Q4 2025 per AQST's latest filing, down from $29.9 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $51.6 million in Q4 2021 and bottomed at $16.1 million in Q1 2024.
  • Average Non-Current Debt over 5 years is $32.2 million, with a median of $32.6 million recorded in 2021.
  • Peak YoY movement for Non-Current Debt: tumbled 52.53% in 2023, then soared 109.36% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $51.6 million in 2021, then tumbled by 35.12% to $33.4 million in 2022, then dropped by 17.76% to $27.5 million in 2023, then increased by 18.15% to $32.5 million in 2024, then decreased by 15.33% to $27.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $27.5 million in Q4 2025, $29.9 million in Q3 2025, and $31.8 million in Q2 2025.